Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOPPatrizia Pregno, Umberto Vitolo, Massimo Menga et al.|Blood|2012Cited by 238
68Ga-PSMA-11 PET/CT in recurrent hormone-sensitive prostate cancer (HSPC): a prospective single-centre study in patients eligible for salvage therapyDésirèe Deandreis, Paolo Gontero, Alessia Guarneri et al.|European Journal of Nuclear Medicine and Molecular Imaging|2020Cited by 39
Event-free survival after 68 Ga-PSMA-11 PET/CT in recurrent hormone-sensitive prostate cancer (HSPC) patients eligible for salvage therapyFrancesco Ceci, Désirèe Deandreis, Guido Rovera et al.|European Journal of Nuclear Medicine and Molecular Imaging|2022Cited by 26
Interim 18-FDG-Positron Emission Tomography/Computed Tomography (PET) Failed to Predict Different Outcome in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Treated with Rituximab-CHOP.Patrizia Pregno, Umberto Vitolo, Annalisa Chiappella et al.|Blood|2009Cited by 12
Yttrium-90 ibritumomab tiuxetan (Zevalin) followed by BEAM (Z-BEAM) conditioning regimen and autologous stem cell transplantation (ASCT) in relapsed or refractory high-risk B-cell non-Hodgkin lymphoma (NHL): a single institution Italian experienceChiara Ciochetto, Umberto Vitolo, Barbara Botto et al.|Annals of Hematology|2018Cited by 7